Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Endometrium.
暂无分享,去创建一个
T. Longacre | C. Otis | R. Zaino | G. Mutter | Michael B Cohen | E. Jarboe | L. Chuang | R. Broaddus | Michael B. Cohen
[1] M. Dowsett,et al. HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. , 2018, Journal of oncology practice.
[2] A. Talhouk,et al. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. , 2015, Gynecologic oncology.
[3] E. Kuipers,et al. Somatic aberrations of mismatch repair genes as a cause of microsatellite‐unstable cancers , 2014, The Journal of pathology.
[4] W. Frankel,et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. , 2014, Gastroenterology.
[5] P. Ascierto,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.
[6] Liang Cheng,et al. Molecular pathology of malignant melanoma: changing the clinical practice paradigm toward a personalized approach. , 2014, Human pathology.
[7] Sharon Nofech-Mozes,et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. , 2014, Archives of pathology & laboratory medicine.
[8] Donna M. Gress,et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum. , 2014, Archives of pathology & laboratory medicine.
[9] A. Lazar,et al. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma , 2013, Cancer.
[10] A. D. Van den Abbeele,et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] A. Rosenwald,et al. Recent advances in de novo CD5+ diffuse large B cell lymphoma , 2013, American journal of hematology.
[12] S. Leung,et al. Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas , 2013, The American journal of surgical pathology.
[13] B. Bastian,et al. Targeting activated KIT signaling for melanoma therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] L. Medeiros,et al. The Impact of MYC Rearrangements and “Double Hit” Abnormalities in Diffuse Large B-Cell Lymphoma , 2013, Current Hematologic Malignancy Reports.
[15] W. Choi,et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.
[16] K. Flaherty,et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[18] W. Choi,et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. , 2013, Blood.
[19] S. O'toole,et al. BRAF inhibitor activity in V600R metastatic melanoma. , 2013, European journal of cancer.
[20] Robert N. Anderson,et al. Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels , 2013, Journal of the National Cancer Institute.
[21] L. Staudt,et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[23] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[24] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[25] L. Medeiros,et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome , 2012, Modern Pathology.
[26] L. Staudt,et al. BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab , 2011, Clinical Cancer Research.
[27] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[28] C. Antonescu,et al. KIT as a therapeutic target in metastatic melanoma. , 2011, JAMA.
[29] Philip M Kluin,et al. Double-hit B-cell lymphomas. , 2011, Blood.
[30] Kai Fu,et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. Gunn,et al. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity , 2010, BMC Cancer.
[32] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[33] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Kai Fu,et al. A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy , 2009, Clinical Cancer Research.
[35] Suet Yi Leung,et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1 , 2009, Nature Genetics.
[36] I. Miura,et al. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations , 2009, Leukemia.
[37] L. Layfield,et al. Effects of Fixative and Fixation Protocols on Assessment of Her-2/neu Oncogene Amplification Status by Fluorescence In Situ Hybridization , 2007, Applied immunohistochemistry & molecular morphology : AIMM.
[38] B. Coiffier. Treatment of diffuse large B-cell lymphoma. , 2005, Current hematology reports.
[39] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[40] P. Tan,et al. Effect of Fixation Period on HER2/neu Gene Amplification Detected by Fluorescence In Situ Hybridization in Invasive Breast Carcinoma , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[41] C. Jones,et al. Routine Acid Decalcification of Bone Marrow Samples Can Preserve DNA for FISH and CGH Studies in Metastatic Prostate Cancer , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.